Very low-dose vemurafenib maintenance for cardiac Erdheim Chester disease
Authors:
Open Access
- 11 April 2025
- journal article
- other
- Published by Springer Nature in Blood Research
- Vol. 60 (1) , 1-4
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Case report: Targeted treatment strategies for Erdheim-Chester diseaseFrontiers in Oncology, 2024
- Cardiac involvement resolution is frequent and associated with improved outcome in Erdheim-Chester diseaseBlood Advances, 2023
- Low-dose vemurafenib monotherapy in BRAFV600E-mutated Erdheim-Chester diseaseLeukemia & Lymphoma, 2020
- Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular eraBlood, 2020
- Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester DiseaseThe Oncologist, 2019
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell HistiocytosisJAMA Oncology, 2018
- Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)Blood, 2017
- Clinical Pharmacokinetics of VemurafenibClinical Pharmacokinetics, 2017
- Cardiac involvement in Erdheim-Chester disease: an MRI studyBlood, 2016
- Erdheim-Chester Disease with Prominent Pericardial Involvement: Clinical, Radiologic, and Histologic FindingsThe American Journal of the Medical Sciences, 2002